TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Healthcare Industry News OS Therapies eyes global approvals for OST-HER2 after breakthrough osteosarcoma vaccine trial OS Therapies’ OST-HER2 cancer vaccine shows strong survival gains in Phase IIb osteosarcoma trial—discover what comes next for global approval. byPallavi MadhirajuOctober 11, 2025